Zacks Investment Research downgraded shares of APPRICUS BIOSCI (APRI) from OUTPERFORM to NEUTRAL on January 30, 2015, with a target price of $1.50.
Apricus Bio operates in the pharmaceutical industry and focuses on research and development in the area of drug delivery. Its proprietary drug delivery technology is called NexACT . Backed by revenue generating CRO business, Bio-Quant, Inc. and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. The Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. Apricus Bio was formerly known as NexMed, Inc and is headquartered in San Diago, California.
To get a free copy of the research report on APPRICUS BIOSCI (APRI),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment